TY - JOUR
T1 - Innovation of therapeutics and prophylaxis for prion diseases
AU - Doh-ura, Katsumi
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2009
Y1 - 2009
N2 - There is no established treatment for prion diseases; however, recently several drug candidates, including pentosan polysulfate and doxycycline, have been clinically used on a trial basis to prevent accumulation of abnormal prion protein in the brain. So far the outcome of the trials is still very far from the goal where a complete cure of the diseases is expected. In order to bridge the gap between the reality and the ideal, the followings are suggested. First, combination therapy needs to be developed against multi-targets: inhibition of prion replication; degradation and scavengery of prion; inhibition of prion-related neurodegeneration. Secondly, preclinical diagnostic means, by which healthy prion-carriers can be revealed before the onset of the diseases, should be explored for earlier therapeutic interventions. The last is to disclose intrinsic disease susceptibility factors and environmental factors, both of which could solely or jointly facilitate in suppressing prion replication and disease progress. Exploitation of these items should be tough but will be deserved for overcoming the fatal diseases.
AB - There is no established treatment for prion diseases; however, recently several drug candidates, including pentosan polysulfate and doxycycline, have been clinically used on a trial basis to prevent accumulation of abnormal prion protein in the brain. So far the outcome of the trials is still very far from the goal where a complete cure of the diseases is expected. In order to bridge the gap between the reality and the ideal, the followings are suggested. First, combination therapy needs to be developed against multi-targets: inhibition of prion replication; degradation and scavengery of prion; inhibition of prion-related neurodegeneration. Secondly, preclinical diagnostic means, by which healthy prion-carriers can be revealed before the onset of the diseases, should be explored for earlier therapeutic interventions. The last is to disclose intrinsic disease susceptibility factors and environmental factors, both of which could solely or jointly facilitate in suppressing prion replication and disease progress. Exploitation of these items should be tough but will be deserved for overcoming the fatal diseases.
KW - Combination therapy
KW - Disease susceptibility
KW - Preclinical diagnosis
KW - Prion disease
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=77956197684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956197684&partnerID=8YFLogxK
U2 - 10.5692/clinicalneurol.49.946
DO - 10.5692/clinicalneurol.49.946
M3 - Article
C2 - 20030256
AN - SCOPUS:77956197684
SN - 0009-918X
VL - 49
SP - 946
EP - 948
JO - Clinical Neurology
JF - Clinical Neurology
IS - 11
ER -